A phase 1 study reveals promising safety and efficacy of NBTXR3 combined with radiotherapy and immunotherapy for resistant melanoma patients.
Jason Chan, MD
Jason Chan, MD, is a radiation oncologist at the University of California San Francisco.
Articles by Jason Chan, MD